Subscribe

Bausch + Lomb Corporation (BLCO.TO)

CAD22.80 +0.41 (+1.83%)
CA TSX Healthcare Medical - Instruments & Supplies
Address 520 Applewood Crescent L4K 4B4
Vaughan, ON, CA
CEO Brenton L. Saunders
Website bausch.com
IPO 2022-05-06
ISIN CA0717051076

Explore sections of this company profile

Also trades on New York Stock Exchange · BLCO (USD) Toronto Stock Exchange · BLCO.TO (CAD)
Description

Bausch + Lomb Corporation is a global leader in eye health, delivering a wide range of products and services across the world. Its business is divided into three key areas: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care sector offers an extensive selection of contact lenses, covering options from daily disposables to frequently replaced types, in addition to lens care solutions, non-prescription eye drops, and vitamin and mineral supplements designed to alleviate conditions such as eye allergies, conjunctivitis, and dry eye. Within the Ophthalmic Pharmaceuticals division, the company develops and markets both proprietary and generic medications for post-operative recovery and the management of ophthalmic conditions like glaucoma, ocular hypertension, and retinal diseases, alongside therapeutic contact lenses. Finally, the Surgical segment equips medical professionals with advanced tools and technologies for cataract, vitreous, and retinal treatments, including intraocular lenses with their specialized delivery systems, phacoemulsification apparatus, and other essential surgical instruments. Founded in 1853, Bausch + Lomb's headquarters are situated in Vaughan, Canada.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CAD22.80 +0.41 (+1.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.0K
Beta
0.58
Float Shares
37.82M
Free Float %
10.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.18% -0.55% -4.29% -4.17% -6.06% -6.82% +32.10% -13.36% -14.31% -14.31% -14.31%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (14 ratings, all time) Hold
Price Targets & DCF
Current price
22.80
DCF (Unlevered) 15.96 -30.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 31% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 3 0
Hold 9 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.94
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +6.5% Q1'26: +9.1% (vs Q1'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -13.3% Q1'26: +66.7% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    -0.8% Q1'26: -5.5% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +6.4% Q1'26: +5.5% (vs Q1'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    +2.8% Q1'26: +2.5% (vs Q1'25)
  • ✓
    Share dilution Medical - Instruments & Supplies: +0.1%
    0.0% Q1'26: +0.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    7.19× Q1'26: 18.37× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.59) × ERP
WACC = 51% × Ke + 49% × Kd (7.8%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 15.96 Current price: 22.80
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
13 Rev. Ana.
13 EPS Ana. 		Dec 2027
13 Rev. Ana.
13 EPS Ana. 		Dec 2028
8 Rev. Ana.
9 EPS Ana. 		Dec 2029
12 Rev. Ana.
11 EPS Ana.
Revenue
3.77B
est: 5.07B (-25.7%)
4.15B
est: 5.40B (-23.3%)
4.79B
est: 4.77B (+0.5%)
5.10B
est: 5.08B (+0.4%)
5.36B
5.33B – 5.38B
+5.5% YoY
5.66B
5.60B – 5.69B
+5.7% YoY
5.97B
5.92B – 5.99B
+5.3% YoY
5.81B
5.77B – 5.84B
-2.6% YoY
EBITDA
599.00M
est: 825.38M (-27.4%)
499.00M
est: 879.88M (-43.3%)
601.00M
est: 711.37M (-15.5%)
747.00M
est: 758.03M (-1.5%)
799.38M
795.68M – 802.89M
+5.5% YoY
844.87M
835.75M – 849.17M
+5.7% YoY
889.91M
882.98M – 894.14M
+5.3% YoY
866.88M
860.12M – 870.99M
-2.6% YoY
EBIT
219.00M
est: 294.57M (-25.7%)
117.00M
est: 314.02M (-62.7%)
165.00M
est: 256.94M (-35.8%)
326.00M
est: 273.80M (+19.1%)
288.73M
287.40M – 290.00M
+5.5% YoY
305.16M
301.87M – 306.72M
+5.7% YoY
321.43M
318.93M – 322.96M
+5.3% YoY
313.11M
310.67M – 314.60M
-2.6% YoY
Net Income
15.00M
est: 381.06M (-96.1%)
-260.00M
est: 235.40M (-210.5%)
-317.00M
est: 206.09M (-253.8%)
-360.00M
est: 187.18M (-292.3%)
276.75M
247.76M – 312.50M
+47.9% YoY
366.95M
314.28M – 393.01M
+32.6% YoY
478.67M
473.82M – 481.63M
+30.4% YoY
617.26M
611.00M – 621.07M
+29.0% YoY
SGA
1.48B
est: 2.01B (-26.4%)
1.74B
est: 2.14B (-19.0%)
2.08B
est: 1.93B (+7.8%)
2.10B
est: 2.06B (+1.8%)
2.17B
2.16B – 2.18B
+5.5% YoY
2.29B
2.27B – 2.31B
+5.7% YoY
2.42B
2.40B – 2.43B
+5.3% YoY
2.35B
2.34B – 2.37B
-2.6% YoY
EPS
0.04
est: 1.08 (-96.0%)
-0.74
est: 0.67 (-211.3%)
-0.90
est: 0.58 (-254.5%)
-1.02
est: 0.53 (-292.8%)
0.78
0.70 – 0.88
+47.9% YoY
1.04
0.89 – 1.11
+32.6% YoY
1.35
1.34 – 1.36
+30.4% YoY
1.74
1.73 – 1.76
+29.0% YoY
Recent Grade Changes (3M)
Date Firm Previous New Grade Action
2026-04-30 Evercore ISI Group In Line In Line Maintain
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-05-01 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
129.90M
OE per share TTM
0.37
Owner's Yield
1.67%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
33.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Ageing Population UCITS ETF AGED.L 0.06% 494.1K 0.40%
2 Goldman Sachs MarketBeta US 1000 Equity ETF GUSA 0.00% 22.6K 0.10%
3 Dimensional - International Core Equity 2 ETF DFIC 0.00% 21.9K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
24.1K
Shares Outstanding
356.54M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Brenton L. Saunders Chief Executive Officer & Chairman 8M male
Osama A. Eldessouky Executive Vice President & Chief Financial Officer 2M male
A. Robert D. Bailey Executive Vice President & Chief Legal Officer 2M male
Yehia Hashad Executive Vice President of Research & Development and Chief Medical officer 2M —
Andrew Stewart President of Global Pharmaceuticals & International Consumer 2M male
Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer — male
George Gadkowski Vice President & Head of Investor Relations & Business Insights — male
Crawford Chief Communications Officer — male
Manisha A. Narasimhan Chief Corporate Development & Digital Officer — —
Alan Waterhouse CPFA Executive Vice President and Chief Supply Chain & Operations Officer — male
Jonathon L. Kellerman Chief Compliance Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies